Beyond bile acids: Targeting farnesoid x receptor (fxr) with natural and synthetic ligands

Current Topics in Medicinal Chemistry

Volumn 14, Issue 19, 2014, Pages 2129-2142

  Carotti, Andrea ^a   Marinozzi, Maura ^a   Custodi, Chiara ^a   Cerra, Bruno ^a   Pellicciari, Roberto ^a,b   Gioiello, Antimo ^a   Macchiarulo, Antonio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b NONE   (Italy)

Author keywords

Bile acid homeostasis; Farnesoid X receptor; Natural ligands; Nuclear receptors; Synthetic ligands

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ALISMA ORIENTALIS EXTRACT; ATRACTYLODES MACROCEPHALA EXTRACT; BENZIMIDAZOLE DERIVATIVE; BILE ACID; EPIGALLOCATECHIN GALLATE; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; FEXARAMINE; GUGGULSTERONE; LIGAND; MULTIDRUG RESISTANCE PROTEIN 1; OLEANOLIC ACID DERIVATIVE; PLANT EXTRACT; PREGNANE X RECEPTOR; PROTEIN; PROTEIN OST ALPHA; PX 102; PX 104; RETINOIC ACID DERIVATIVE; STEROL DERIVATIVE; SULFOTRANSFERASE; SULFOTRANSFERASE 2A1; SUVANINE; TRITERPENE DERIVATIVE; TUROFEXORATE ISOPROPYL; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; PROTEIN BINDING;

ALISMA; ARTICLE; BIOLOGICAL ACTIVITY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; IC50; LUCIFERASE ASSAY; MOLECULAR DOCKING; NONHUMAN; PROTEIN EXPRESSION; SCHISANDRA; SCHISANDRA GLAUCESCENS DIELS; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

ANIMALS; BILE ACIDS AND SALTS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84925844029     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141112094058     Document Type: Article

References (118)

1. Seol, W.; Choi, H.S.; Moore, D.D. Isolation of Proteins That Interact Specifically with the Retinoid X Receptor: Two Novel Orphan Receptors. Mol. Endocrinol., 1995, 9(1), 72–85.
2. Forman, B.M.; Goode, E.; Chen, J.; Oro, A.E.; Bradley, D.J.; Perlmann, T.; Noonan, D.J.; Burka, L.T.; McMorris, T.; Lamph, W.W.; Evans, R.M.; Weinberger, C. Identification of a Nuclear Receptor That Is Activated by Farnesol Metabolites. Cell, 1995, 81(5), 687–693.
3. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M. V; Lustig, K.D.; Mangelsdorf, D.J.; Shan, B. Identification of a Nuclear Receptor for Bile Acids. Science, 1999, 284(5418), 1362–1365.
4. Parks, D.J.; Blanchard, S.G.; Bledsoe, R.K.; Chandra, G.; Consler, T.G.; Kliewer, S.A.; Stimmel, J.B.; Willson, T.M.; Zavacki, A.M.; Moore, D.D.; Lehmann, J.M. Bile Acids: Natural Ligands for an Orphan Nuclear Receptor. Science, 1999, 284(5418), 1365–1368.
5. Wang, H.; Chen, J.; Hollister, K.; Sowers, L.C.; Forman, B.M. Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR. Mol. Cell, 1999, 3(5), 543–553.
6. Liu, Y.; Binz, J.; Numerick, M.J.; Dennis, S.; Luo, G.; Desai, B.; MacKenzie, K.I.; Mansfield, T.A.; Kliewer, S.A.; Goodwin, B.; Jones, S.A. Hepatoprotection by the Farnesoid X Receptor Agonist GW4064 in Rat Models of Intra- and Extrahepatic Cholestasis. J. Clin. Invest., 2003, 112(11), 1678–1687.
7. Stedman, C.; Liddle, C.; Coulter, S.; Sonoda, J.; Alvarez, J.G.; Evans, R.M.; Downes, M. Benefit of Farnesoid X Receptor Inhibition in Obstructive Cholestasis. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(30), 11323–11328.
8. Modica, S.; Petruzzelli, M.; Bellafante, E.; Murzilli, S.; Salvatore, L.; Celli, N.; Di Tullio, G.; Palasciano, G.; Moustafa, T.; Halilbasic, E.; Trauner, M.; Moschetta, A. Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice against Cholestasis. Gastroenterology, 2012, 142(2), 355–65.e1–4.
9. Moschetta, A.; Bookout, A.L.; Mangelsdorf, D.J. Prevention of Cholesterol Gallstone Disease by FXR Agonists in a Mouse Model. Nat. Med., 2004, 10(12), 1352–1358.
10. Ma, K.; Saha, P.K.; Chan, L.; Moore, D.D. Farnesoid X Receptor Is Essential for Normal Glucose Homeostasis. J. Clin. Invest., 2006, 116(4), 1102–1109.
11. Zhang, Y.; Lee, F.Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F.J.; Willson, T.M.; Edwards, P.A. Activation of the Nuclear Receptor FXR Improves Hyperglycemia and Hyperlipidemia in Diabetic Mice. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(4), 1006–1011.
12. Inagaki, T.; Moschetta, A.; Lee, Y.-K.; Peng, L.; Zhao, G.; Downes, M.; Yu, R.T.; Shelton, J.M.; Richardson, J.A.; Repa, J.J.; Mangelsdorf, D.J.; Kliewer, S.A. Regulation of Antibacterial Defense in the Small Intestine by the Nuclear Bile Acid Receptor. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(10), 3920–3925.
13. Huang, W.; Ma, K.; Zhang, J.; Qatanani, M.; Cuvillier, J.; Liu, J.; Dong, B.; Huang, X.; Moore, D.D. Nuclear Receptor-Dependent Bile Acid Signaling Is Required for Normal Liver Regeneration. Science, 2006, 312(5771), 233–236.
14. Chen, W.-D.; Wang, Y.-D.; Meng, Z.; Zhang, L.; Huang, W. Nuclear Bile Acid Receptor FXR in the Hepatic Regeneration. Biochim. Biophys. Acta, 2011, 1812(8), 888–892.
15. Zhang, L.; Wang, Y.-D.; Chen, W.-D.; Wang, X.; Lou, G.; Liu, N.; Lin, M.; Forman, B.M.; Huang, W. Promotion of Liver Regeneration/repair by Farnesoid X Receptor in Both Liver and Intestine in Mice. Hepatology, 2012, 56(6), 2336–2343.
16. Maran, R.R.M.; Thomas, A.; Roth, M.; Sheng, Z.; Esterly, N.; Pinson, D.; Gao, X.; Zhang, Y.; Ganapathy, V.; Gonzalez, F.J.; Guo, G.L. Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development. J. Pharmacol. Exp. Ther., 2009, 328(2), 469–477.
17. Modica, S.; Murzilli, S.; Salvatore, L.; Schmidt, D.R.; Moschetta, A. Nuclear Bile Acid Receptor FXR Protects against Intestinal Tumorigenesis. Cancer Res., 2008, 68(23), 9589–9594.
18. Kim, I.; Morimura, K.; Shah, Y.; Yang, Q.; Ward, J.M.; Gonzalez, F.J. Spontaneous Hepatocarcinogenesis in Farnesoid X Receptor- Null Mice. Carcinogenesis, 2007, 28(5), 940–946.
19. Yang, F.; Huang, X.; Yi, T.; Yen, Y.; Moore, D.D.; Huang, W. Spontaneous Development of Liver Tumors in the Absence of the Bile Acid Receptor Farnesoid X Receptor. Cancer Res., 2007, 67(3), 863–867.
20. Deuschle, U.; Schüler, J.; Schulz, A.; Schlüter, T.; Kinzel, O.; Abel, U.; Kremoser, C. FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model. PLoS One, 2012, 7(10), e43044.
21. Fujino, T.; Takeuchi, A.; Maruko-Ohtake, A.; Ohtake, Y.; Satoh, J.; Kobayashi, T.; Tanaka, T.; Ito, H.; Sakamaki, R.; Kashimura, R.; Ando, K.; Nishimaki-Mogami, T.; Ohkubo, Y.; Kitamura, N.; Sato, R.; Kikugawa, K.; Hayakawa, M. Critical Role of Farnesoid X Receptor for Hepatocellular Carcinoma Cell Proliferation. J. Biochem., 2012, 152(6), 577–586.
22. Wang, X.X.; Jiang, T.; Shen, Y.; Caldas, Y.; Miyazaki-Anzai, S.; Santamaria, H.; Urbanek, C.; Solis, N.; Scherzer, P.; Lewis, L.; Gonzalez, F.J.; Adorini, L.; Pruzanski, M.; Kopp, J.B.; Verlander, J.W.; Levi, M. Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model. Diabetes, 2010, 59(11), 2916–2927.
23. Morelli, A.; Vignozzi, L.; Maggi, M.; Adorini, L. Farnesoid X Receptor Activation Improves Erectile Dysfunction in Models of Metabolic Syndrome and Diabetes. Biochim. Biophys. Acta, 2011, 1812(8), 859–866.
24. Zhang, R.; Ran, H.-H.; Zhang, Y.-X.; Liu, P.; Lu, C.-Y.; Xu, Q.; Huang, Y. Farnesoid X Receptor Regulates Vascular Reactivity through Nitric Oxide Mechanism. J. Physiol. Pharmacol., 2012, 63(4), 367–372.
25. Zhang, L.; Li, T.; Yu, D.; Forman, B.M.; Huang, W. FXR Protects Lung from Lipopolysaccharide-Induced Acute Injury. Mol. Endocrinol., 2012, 26(1), 27–36.
26. Adorini, L.; Pruzanski, M.; Shapiro, D. Farnesoid X Receptor Targeting to Treat Nonalcoholic Steatohepatitis. Drug Discov. Today, 2012, 17(17-18), 988–997.
27. Gadaleta, R.M.; van Erpecum, K.J.; Oldenburg, B.; Willemsen, E.C.L.; Renooij, W.; Murzilli, S.; Klomp, L.W.J.; Siersema, P.D.; Schipper, M.E.I.; Danese, S.; Penna, G.; Laverny, G.; Adorini, L.; Moschetta, A.; van Mil, S.W.C. Farnesoid X Receptor Activation Inhibits Inflammation and Preserves the Intestinal Barrier in Inflammatory Bowel Disease. Gut, 2011, 60(4), 463–472.
28. Satyavati, G. V. Guggulipid: A Promising Hypolipedemic Agent from Gum Guggul (Commiphora Wightii). In Economic and Medicinal Plant Research;; Plants and traditional medicine; New York: Academic Press, 1991; pp. 47–82.
29. Zhu, N.; Rafi, M.M.; DiPaola, R.S.; Xin, J.; Chin, C.K.; Badmaev, V.; Ghai, G.; Rosen, R.T.; Ho, C.T. Bioactive Constituents from Gum Guggul (Commiphora Wightii). Phytochemistry, 2001, 56(7), 723–727.
30. Gioiello, A.; Sardella, R.; Rosatelli, E.; Sadeghpour, B.M.; Natalini, B.; Pellicciari, R. Novel Stereoselective Synthesis and Chromatographic Evaluation of E-Guggulsterone. Steroids, 2012, 77(3), 250–254.
31. Ham, J.; Chin, J.; Kang, H. A Regioselective Synthesis of EGuggulsterone. Molecules, 2011, 16(12), 4165–4171.
32. Urizar, N.L.; Liverman, A.B.; Dodds, D.T.; Silva, F.V.; Ordentlich, P.; Yan, Y.; Gonzalez, F.J.; Heyman, R.A.; Mangelsdorf, D.J.; Moore, D.D. A Natural Product That Lowers Cholesterol as an Antagonist Ligand for FXR. Science, 2002, 296(5573), 1703–1706.
33. Cui, J.; Huang, L.; Zhao, A.; Lew, J.-L.; Yu, J.; Sahoo, S.; Meinke, P.T.; Royo, I.; Pelaez, F.; Wright, S.D. Guggulsterone Is a Farnesoid X Receptor Antagonist in Coactivator Association Assays but Acts to Enhance Transcription of Bile Salt Export Pump. J. Biol. Chem., 2003, 278(12), 10214–10220.
34. Wu, J.; Xia, C.; Meier, J.; Li, S.; Hu, X.; Lala, D.S. The Hypolipidemic Natural Product Guggulsterone Acts as an Antagonist of the Bile Acid Receptor. Mol. Endocrinol., 2002, 16(7), 1590–1597.
35. Meyer, U.; Costantino, G.; Macchiarulo, A.; Pellicciari, R. Is Antagonism of E/Z-Guggulsterone at the Farnesoid X Receptor Mediated by a Noncanonical Binding Site? A Molecular Modeling Study. J. Med. Chem., 2005, 48(22), 6948–6955.
36. Yang, L.; Broderick, D.; Jiang, Y.; Hsu, V.; Maier, C.S. Conformational Dynamics of Human FXR-LBD Ligand Interactions Studied by Hydrogen/deuterium Exchange Mass Spectrometry: Insights into the Antagonism of the Hypolipidemic Agent Z-Guggulsterone. Biochim. Biophys. Acta, 2014.
37. Pellicciari, R.; Gioiello, A.; Costantino, G.; Sadeghpour, B.M.; Rizzo, G.; Meyer, U.; Parks, D.J.; Entrena-Guadix, A.; Fiorucci, S. Back Door Modulation of the Farnesoid X Receptor: Design, Synthesis, and Biological Evaluation of a Series of Side Chain Modified Chenodeoxycholic Acid Derivatives. J. Med. Chem., 2006, 49(14), 4208–4215.
38. Gioiello, A.; Macchiarulo, A.; Carotti, A.; Filipponi, P.; Costantino, G.; Rizzo, G.; Adorini, L.; Pellicciari, R. Extending SAR of Bile Acids as FXR Ligands: Discovery of 23-N- (carbocinnamyloxy)-3,7-Dihydroxy-6-Ethyl-24-nor-5-Cholan- 23-Amine. Bioorg. Med. Chem., 2011, 19(8), 2650–2658.
39. Scholtes, C.; André, P.; Trépo, C.; Cornu, C.; Remontet, L.; Ecochard, R.; Bejan-Angoulvant, T.; Gueyffier, F. Farnesoid X Receptor Targeting for Hepatitis C: Study Protocol for a Proof-of- Concept Trial. Therapie, 2012, 67(5), 423–427.
40. Sanodiya, B.S.; Thakur, G.S.; Baghel, R.K.; Prasad, G.B.K.S.; Bisen, P.S. Ganoderma Lucidum: A Potent Pharmacological Macrofungus. Curr. Pharm. Biotechnol., 2009, 10(8), 717–742.
41. Grienke, U.; Mihály-Bison, J.; Schuster, D.; Afonyushkin, T.; Binder, M.; Guan, S.; Cheng, C.; Wolber, G.; Stuppner, H.; Guo, D.; Bochkov, V.N.; Rollinger, J.M. Pharmacophore-Based Discovery of FXR-Agonists. Part II: Identification of Bioactive Triterpenes from Ganoderma Lucidum. Bioorg. Med. Chem., 2011, 19(22), 6779–6791.
42. Zou, J.; Yang, L.-B.; Jiang, J.; Diao, Y.-Y.; Li, X.-N.; Huang, J.; Yang, J.-H.; Li, H.-L.; Xiao, W.-L.; Du, X.; Shang, S.-Z.; Pu, J.-X.; Sun, H.-D. Lanostane Triterpenoids from the Stems of Schisandra Glaucescens. Planta Med., 2012, 78(5), 472–479.
43. Zou, J.; Jiang, J.; Diao, Y.-Y.; Yang, L.-B.; Huang, J.; Li, H.-L.; Du, X.; Xiao, W.-L.; Pu, J.-X.; Sun, H.-D. Cycloartane Triterpenoids from the Stems of Schisandra Glaucescens and Their Bioactivity. Fitoterapia, 2012, 83(5), 926–931.
44. Tsai, C.-J.; Liang, J.-W.; Lin, H.-R. Sesquiterpenoids from Atractylodes Macrocephala Act as Farnesoid X Receptor and Progesterone Receptor Modulators. Bioorg. Med. Chem. Lett., 2012, 22(6), 2326–2329.
45. Lin, H.-R. Triterpenes from Alisma Orientalis Act as Farnesoid X Receptor Agonists. Bioorg. Med. Chem. Lett., 2012, 22(14), 4787–4792.
46. Peng, G.-P.; Tian, G.; Huang, X.-F.; Lou, F.-C. Guaiane-Type Sesquiterpenoids from Alisma Orientalis. Phytochemistry, 2003, 63(8), 877–881.
47. Hu, X.-Y.; Guo, Y.-Q.; Gao, W.-Y.; Zhang, T.-J.; Chen, H.-X. Two New Triterpenes from the Rhizomes of Alisma Orientalis. J. Asian Nat. Prod. Res., 2008, 10(5-6), 481–484.
48. Yoshikawa, M.; Matsuda, H. Antidiabetogenic Activity of Oleanolic Acid Glycosides from Medicinal Foodstuffs. Biofactors, 2000, 13(1-4), 231–237.
49. Dzubak, P.; Hajduch, M.; Vydra, D.; Hustova, A.; Kvasnica, M.; Biedermann, D.; Markova, L.; Urban, M.; Sarek, J. Pharmacological Activities of Natural Triterpenoids and Their Therapeutic Implications. Nat. Prod. Rep., 2006, 23(3), 394–411.
50. Sun, H.; Fang, W.; Wang, W.; Hu, C. Structure-Activity Relationships of Oleanane- and Ursane- Type Triterpenoids. Bot. Stud., 2006, 47, 339–368.
51. Genet, C.; Strehle, A.; Schmidt, C.; Boudjelal, G.; Lobstein, A.; Schoonjans, K.; Souchet, M.; Auwerx, J.; Saladin, R.; Wagner, A. Structure-Activity Relationship Study of Betulinic Acid, a Novel and Selective TGR5 Agonist, and Its Synthetic Derivatives: Potential Impact in Diabetes. J. Med. Chem., 2010, 53, 178–190.
52. Liu, W.; Wong, C. Oleanolic Acid Is a Selective Farnesoid X Receptor Modulator. Phytother. Res., 2010, 24, 369–373.
53. Nam, S.-J.; Ko, H.; Ju, M.K.; Hwang, H.; Chin, J.; Ham, J.; Lee, B.; Lee, J.; Won, D.H.; Choi, H.; Ko, J.; Shin, K.; Oh, T.; Kim, S.; Rho, J.-R.; Kang, H. Scalarane Sesterterpenes from a Marine Sponge of the Genus Spongia and Their FXR Antagonistic Activity. J. Nat. Prod., 2007, 70(11), 1691–1695.
54. Nam, S.-J.; Ko, H.; Shin, M.; Ham, J.; Chin, J.; Kim, Y.; Kim, H.; Shin, K.; Choi, H.; Kang, H. Farnesoid X-Activated Receptor Antagonists from a Marine Sponge Spongia Sp. Bioorg. Med. Chem. Lett., 2006, 16(20), 5398–5402.
55. Di Leva, F.S.; Festa, C.; D’Amore, C.; De Marino, S.; Renga, B.; D’Auria, M.V.; Novellino, E.; Limongelli, V.; Zampella, A.; Fiorucci, S. Binding Mechanism of the Farnesoid X Receptor Marine Antagonist Suvanine Reveals a Strategy to Forestall Drug Modulation on Nuclear Receptors. Design, Synthesis, and Biological Evaluation of Novel Ligands. J. Med. Chem., 2013, 56(11), 4701–4717.
56. Kobayashi, M.; Hayashi, K.; Kawazoe, K.; Kitagawa, I. Marine Natural-Products.29. Heterosigma-Glycolipid-I,Heterosigma- Glycolipid-Ii, Heterosigma-Glycolipid-Iii, Andheterosigma- Glycolipid-Iv, 4 Diacylglyceroglycolipidspossessing Omega-3- Polyunsaturated Fatty-Acid Residues, Fromthe Raphidophycean Dinoflagell. Chem. Pharm. Bull. (Tokyo)., 1992, 40, 1404–1410.
57. De Marino, S.; Sepe, V.; D’Auria, M.V.; Bifulco, G.; Renga, B.; Petek, S.; Fiorucci, S.; Zampella, A. Towards New Ligands of Nuclear Receptors. Discovery of Malaitasterol A, an Unique Bis- Secosterol from Marine Sponge Theonella Swinhoei. Org. Biomol. Chem., 2011, 9(13), 4856–4862.
58. Renga, B.; Mencarelli, A.; D’Amore, C.; Cipriani, S.; D’Auria, M.V.; Sepe, V.; Chini, M.G.; Monti, M.C.; Bifulco, G.; Zampella, A.; Fiorucci, S. Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis. PLoS One, 2012, 7(1), e30443.
59. Sepe, V.; Ummarino, R.; D’Auria, M.V.; Chini, M.G.; Bifulco, G.; Renga, B.; D’Amore, C.; Debitus, C.; Fiorucci, S.; Zampella, A. Conicasterol E, a Small Heterodimer Partner Sparing Farnesoid X Receptor Modulator Endowed with a Pregnane X Receptor Agonistic Activity, from the Marine Sponge Theonella Swinhoei. J. Med. Chem., 2012, 55(1), 84–93.
60. De Marino, S.; Ummarino, R.; D’Auria, M.V.; Chini, M.G.; Bifulco, G.; D’Amore, C.; Renga, B.; Mencarelli, A.; Petek, S.; Fiorucci, S.; Zampella, A. 4-Methylenesterols from Theonella Swinhoei Sponge Are Natural Pregnane-X-Receptor Agonists and Farnesoid-X-Receptor Antagonists That Modulate Innate Immunity. Steroids, 2012, 77(5), 484–495.
61. Fiorucci, S.; Distrutti, E.; Bifulco, G.; D’Auria, M.V.; Zampella, A. Marine Sponge Steroids as Nuclear Receptor Ligands. Trends Pharmacol. Sci., 2012, 33(11), 591–601.
62. De Marino, S.; Ummarino, R.; D’Auria, M.V.; Chini, M.G.; Bifulco, G.; Renga, B.; D’Amore, C.; Fiorucci, S.; Debitus, C.; Zampella, A. Theonellasterols and Conicasterols from Theonella Swinhoei. Novel Marine Natural Ligands for Human Nuclear Receptors. J. Med. Chem., 2011, 54(8), 3065–3075.
63. Zhang, H.-J.; Yi, Y.-H.; Lin, H.-W. Oxygenated 4-Methylidene Sterols from the South China Sea Sponge Theonella Swinhoei. Helv. Chim. Acta, 2010, 93(6), 1120–1126.
64. Angawi, R.F.; Calcinai, B.; Cerrano, C.; Dien, H.A.; Fattorusso, E.; Scala, F.; Taglialatela-Scafati, O. Dehydroconicasterol and Aurantoic Acid, a Chlorinated Polyene Derivative, from the Indonesian Sponge Theonella Swinhoei. J. Nat. Prod., 2009, 72(12), 2195–2198.
65. Qureshi, A.; Faulkner, D.J. 7alpha-Hydroxytheonellasterol, a Cytotoxic 4-Methylene Sterol from the Philippines Sponge Theonella Swinhoei. J. Nat. Prod., 2000, 63(6), 841–842.
66. Sugo, Y.; Inouye, Y.; Nakayama, N. Structures of Nine Oxygenated 4-Methylene Sterols from Hachijo Marine Sponge Theonella Swinhoei. Steroids, 1995, 60(11), 738–742.
67. Comin, M.J.; Maier, M.S.; Roccatagliata, A.J.; Pujol, C.A.; Damonte, E.B. Evaluation of the Antiviral Activity of Natural Sulfated Polyhydroxysteroids and Their Synthetic Derivatives and Analogs. Steroids, 1999, 64(5), 335–340.
68. Fu, X.; Schmitz, F.J.; Lee, R.H.; Papkoff, J.S.; Slate, D.L. Inhibitors of Protein Tyrosine Kinase pp60v-Src: Sterol Sulfates from the Brittle Star Ophiarachna Incrassata. J. Nat. Prod., 1994, 57(11), 1591–1594.
69. McKee, T.C.; Cardellina, J.H.; Riccio, R.; D’Auria, M. V; Iorizzi, M.; Minale, L.; Moran, R.A.; Gulakowski, R.J.; McMahon, J.B.; Buckheit, R.W. HIV-Inhibitory Natural Products. 11. Comparative Studies of Sulfated Sterols from Marine Invertebrates. J. Med. Chem., 1994, 37(6), 793–797.
70. Roccatagliata, A.; Maier, M.; Seldes, A. New Sulfated Polyhydroxysteroids from the Antarctic Ophiuroid Astrotomaagassizii. J. Nat. Prod., 1998, 61(3), 370–374.
71. Sepe, V.; Bifulco, G.; Renga, B.; D’Amore, C.; Fiorucci, S.; Zampella, A. Discovery of Sulfated Sterols from Marine Invertebrates as a New Class of Marine Natural Antagonists of Farnesoid-X-Receptor. J. Med. Chem., 2011, 54(5), 1314–1320.
72. Shin, K.; Chin, J.; Hahn, D.; Lee, J.; Hwang, H.; Won, D.H.; Ham, J.; Choi, H.; Kang, E.; Kim, H.; Ju, M.K.; Nam, S.-J.; Kang, H. Sterols from a Soft Coral, Dendronephthya Gigantea as Farnesoid X-Activated Receptor Antagonists. Steroids, 2012, 77(5), 355–359.
73. Putra, M.Y.; Bavestrello, G.; Cerrano, C.; Renga, B.; D’Amore, C.; Fiorucci, S.; Fattorusso, E.; Taglialatela-Scafati, O. Polyhydroxylated Sterols from the Indonesian Soft Coral Sinularia Sp. and Their Effect on Farnesoid X-Activated Receptor. Steroids, 2012, 77(5), 433–440.
74. Chyu, K.-Y.; Babbidge, S.M.; Zhao, X.; Dandillaya, R.; Rietveld, A.G.; Yano, J.; Dimayuga, P.; Cercek, B.; Shah, P.K. Differential Effects of Green Tea-Derived Catechin on Developing versus Established Atherosclerosis in Apolipoprotein E-Null Mice. Circulation, 2004, 109(20), 2448–2453.
75. Donà, M.; Dell’Aica, I.; Calabrese, F.; Benelli, R.; Morini, M.; Albini, A.; Garbisa, S. Neutrophil Restraint by Green Tea: Inhibition of Inflammation, Associated Angiogenesis, and Pulmonary Fibrosis. J. Immunol., 2003, 170(8), 4335–4341.
76. Frei, B.; Higdon, J. V. Antioxidant Activity of Tea Polyphenols in vivo: Evidence from Animal Studies. J. Nutr., 2003, 133(10), 3275S–84S.
77. Raederstorff, D.G.; Schlachter, M.F.; Elste, V.; Weber, P. Effect of EGCG on Lipid Absorption and Plasma Lipid Levels in Rats. J. Nutr. Biochem., 2003, 14(6), 326–332.
78. Li, G.; Lin, W.; Araya, J.J.; Chen, T.; Timmermann, B.N.; Guo, G.L. A Tea Catechin, Epigallocatechin-3-Gallate, Is a Unique Modulator of the Farnesoid X Receptor. Toxicol. Appl. Pharmacol., 2012, 258(2), 268–274.
79. Urgert, R.; Katan, M.B. The Cholesterol-Raising Factor from Coffee Beans. Annu. Rev. Nutr., 1997, 17, 305–324.
80. Tverdal, A.; Stensvold, I.; Solvoll, K.; Foss, O.P.; Lund-Larsen, P.; Bjartveit, K. Coffee Consumption and Death from Coronary Heart Disease in Middle Aged Norwegian Men and Women. BMJ, 1990, 300(6724), 566–569.
81. Weusten-Van der Wouw, M.P.; Katan, M.B.; Viani, R.; Huggett, A.C.; Liardon, R.; Lund-Larsen, P.G.; Thelle, D.S.; Ahola, I.; Aro, A. Identity of the Cholesterol-Raising Factor from Boiled Coffee and Its Effects on Liver Function Enzymes. J. Lipid Res., 1994, 35, 721–733.
82. Ricketts, M.-L.; Boekschoten, M. V; Kreeft, A.J.; Hooiveld, G.J.E.J.; Moen, C.J.A.; Müller, M.; Frants, R.R.; Kasanmoentalib, S.; Post, S.M.; Princen, H.M.G.; Porter, J.G.; Katan, M.B.; Hofker, M.H.; Moore, D.D. The Cholesterol-Raising Factor from Coffee Beans, Cafestol, as an Agonist Ligand for the Farnesoid and Pregnane X Receptors. Mol. Endocrinol., 2007, 21(7), 1603–1616.
83. Kuiper, G.G.; Carlsson, B.; Grandien, K.; Enmark, E.; Häggblad, J.; Nilsson, S.; Gustafsson, J.A. Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors Alpha and Beta. Endocrinology, 1997, 138(3), 863–870.
84. Wang, H.; Li, H.; Moore, L.B.; Johnson, M.D.L.; Maglich, J.M.; Goodwin, B.; Ittoop, O.R.R.; Wisely, B.; Creech, K.; Parks, D.J.; Collins, J.L.; Willson, T.M.; Kalpana, G. V; Venkatesh, M.; Xie, W.; Cho, S.Y.; Roboz, J.; Redinbo, M.; Moore, J.T.; Mani, S. The Phytoestrogen Coumestrol Is a Naturally Occurring Antagonist of the Human Pregnane X Receptor. Mol. Endocrinol., 2008, 22(4), 838–857.
85. Takahashi, M.; Kanayama, T.; Yashiro, T.; Kondo, H.; Murase, T.; Hase, T.; Tokimitsu, I.; Nishikawa, J.-I.; Sato, R. Effects of Coumestrol on Lipid and Glucose Metabolism as a Farnesoid X Receptor Ligand. Biochem. Biophys. Res. Commun., 2008, 372(3), 395–399.
86. Epifano, F.; Genovese, S.; James Squires, E.; Gray, M.A. Nelumal A, the Active Principle from Ligularia Nelumbifolia, Is a Novel Farnesoid X Receptor Agonist. Bioorg. Med. Chem. Lett., 2012, 22(9), 3130–3135.
87. Maloney, P.R.; Parks, D.J.; Haffner, C.D.; Fivush, A.M.; Chandra, G.; Plunket, K.D.; Creech, K.L.; Moore, L.B.; Wilson, J.G.; Lewis, M.C.; Jones, S.A.; Willson, T.M. Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR. J. Med. Chem., 2000, 43(16), 2971–2974.
88. Cariou, B.; van Harmelen, K.; Duran-Sandoval, D.; van Dijk, T.H.; Grefhorst, A.; Abdelkarim, M.; Caron, S.; Torpier, G.; Fruchart, J.- C.; Gonzalez, F.J.; Kuipers, F.; Staels, B. The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. J. Biol. Chem., 2006, 281(16), 11039–11049.
89. Watanabe, M.; Houten, S.M.; Wang, L.; Moschetta, A.; Mangelsdorf, D.J.; Heyman, R.A.; Moore, D.D.; Auwerx, J. Bile Acids Lower Triglyceride Levels via a Pathway Involving FXR, SHP, and SREBP-1c. J. Clin. Invest., 2004, 113(10), 1408–1418.
90. Akwabi-Ameyaw, A.; Bass, J.Y.; Caldwell, R.D.; Caravella, J.A.; Chen, L.; Creech, K.L.; Deaton, D.N.; Jones, S.A.; Kaldor, I.; Liu, Y.; Madauss, K.P.; Marr, H.B.; McFadyen, R.B.; Miller, A.B.; Iii, F.N.; Parks, D.J.; Spearing, P.K.; Todd, D.; Williams, S.P.; Wisely, G.B. Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Naphthoic Acid-Based Analogs of GW 4064. Bioorg. Med. Chem. Lett., 2008, 18(15), 4339–4343.
91. Akwabi-Ameyaw, A.; Caravella, J.A.; Chen, L.; Creech, K.L.; Deaton, D.N.; Madauss, K.P.; Marr, H.B.; Miller, A.B.; Navas, F.; Parks, D.J.; Spearing, P.K.; Todd, D.; Williams, S.P.; Wisely, G.B. Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Alternative Replacements of the Stilbene. Bioorg. Med. Chem. Lett., 2011, 21(20), 6154–6160.
92. Akwabi-Ameyaw, A.; Bass, J.Y.; Caldwell, R.D.; Caravella, J.A.; Chen, L.; Creech, K.L.; Deaton, D.N.; Madauss, K.P.; Marr, H.B.; McFadyen, R.B.; Miller, A.B.; Navas, F.; Parks, D.J.; Spearing, P.K.; Todd, D.; Williams, S.P.; Bruce Wisely, G. FXR Agonist Activity of Conformationally Constrained Analogs of GW 4064. Bioorg. Med. Chem. Lett., 2009, 19(16), 4733–4739.
93. Kainuma, M.; Makishima, M.; Hashimoto, Y.; Miyachi, H. Design, Synthesis, and Evaluation of Non-Steroidal Farnesoid X Receptor (FXR) Antagonist. Bioorg. Med. Chem., 2007, 15(7), 2587–2600.
94. Feng, S.; Yang, M.; Zhang, Z.; Wang, Z.; Hong, D.; Richter, H.; Benson, G.M.; Bleicher, K.; Grether, U.; Martin, R.E.; Plancher, J.- M.; Kuhn, B.; Rudolph, M.G.; Chen, L. Identification of an NOxide Pyridine GW4064 Analog as a Potent FXR Agonist. Bioorg. Med. Chem. Lett., 2009, 19(9), 2595–2598.
95. Misawa, T.; Hayashi, H.; Sugiyama, Y.; Hashimoto, Y. Discovery and Structural Development of Small Molecules That Enhance Transport Activity of Bile Salt Export Pump Mutant Associated with Progressive Familial Intrahepatic Cholestasis Type 2. Bioorg. Med. Chem., 2012, 20(9), 2940–2949.
96. Nicolaou, K.C.; Evans, R.M.; Roecker, A.J.; Hughes, R.; Downes, M.; Pfefferkorn, J.A. Discovery and Optimization of Non-Steroidal FXR Agonists from Natural Product-like Libraries. Org. Biomol. Chem., 2003, 1(6), 908–920.
97. Burris, T.P.; Solt, L. a; Wang, Y.; Crumbley, C.; Banerjee, S.; Griffett, K.; Lundasen, T.; Hughes, T.; Kojetin, D.J. Nuclear Receptors and Their Selective Pharmacologic Modulators. Pharmacol. Rev., 2013, 65, 710–778.
98. Flatt, B.; Martin, R.; Wang, T.-L.; Mahaney, P.; Murphy, B.; Gu, X.-H.; Foster, P.; Li, J.; Pircher, P.; Petrowski, M.; Schulman, I.; Westin, S.; Wrobel, J.; Yan, G.; Bischoff, E.; Daige, C.; Mohan, R. Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR). J. Med. Chem., 2009, 52(4), 904–907.
99. Evans, M.J.; Mahaney, P.E.; Borges-Marcucci, L.; Lai, K.; Wang, S.; Krueger, J.A.; Gardell, S.J.; Huard, C.; Martinez, R.; Vlasuk, G.P.; Harnish, D.C. A Synthetic Farnesoid X Receptor (FXR) Agonist Promotes Cholesterol Lowering in Models of Dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296(3), G543–52.
100. Mehlmann, J.F.; Crawley, M.L.; Lundquist, J.T.; Unwalla, R.J.; Harnish, D.C.; Evans, M.J.; Kim, C.Y.; Wrobel, J.E.; Mahaney, P.E. Pyrrole[2,3-D]azepino Compounds as Agonists of the Farnesoid X Receptor (FXR). Bioorg. Med. Chem. Lett., 2009, 19(18), 5289–5292.
101. Lundquist, J.T.; Harnish, D.C.; Kim, C.Y.; Mehlmann, J.F.; Unwalla, R.J.; Phipps, K.M.; Crawley, M.L.; Commons, T.; Green, D.M.; Xu, W.; Hum, W.-T.; Eta, J.E.; Feingold, I.; Patel, V.; Evans, M.J.; Lai, K.; Borges-Marcucci, L.; Mahaney, P.E.; Wrobel, J.E. Improvement of Physiochemical Properties of the Tetrahydroazepinoindole Series of Farnesoid X Receptor (FXR) Agonists: Beneficial Modulation of Lipids in Primates. J. Med. Chem., 2010, 53(4), 1774–1787.
102. Richter, H.G.F.; Benson, G.M.; Blum, D.; Chaput, E.; Feng, S.; Gardes, C.; Grether, U.; Hartman, P.; Kuhn, B.; Martin, R.E.; Plancher, J.-M.; Rudolph, M.G.; Schuler, F.; Taylor, S.; Bleicher, K.H. Discovery of Novel and Orally Active FXR Agonists for the Potential Treatment of Dyslipidemia & Diabetes. Bioorg. Med. Chem. Lett., 2011, 21(1), 191–194.
103. Richter, H.G.F.; Benson, G.M.; Bleicher, K.H.; Blum, D.; Chaput, E.; Clemann, N.; Feng, S.; Gardes, C.; Grether, U.; Hartman, P.; Kuhn, B.; Martin, R.E.; Plancher, J.-M.; Rudolph, M.G.; Schuler, F.; Taylor, S. Optimization of a Novel Class of Benzimidazole- Based Farnesoid X Receptor (FXR) Agonists to Improve Physicochemical and ADME Properties. Bioorg. Med. Chem. Lett., 2011, 21(4), 1134–1140.
104. Dussault, I.; Beard, R.; Lin, M.; Hollister, K.; Chen, J.; Xiao, J.-H.; Chandraratna, R.; Forman, B.M. Identification of Gene-Selective Modulators of the Bile Acid Receptor FXR. J. Biol. Chem., 2003, 278(9), 7027–7033.
105. Deng, G.; Li, W.; Shen, J.; Jiang, H.; Chen, K.; Liu, H. Pyrazolidine-3,5-Dione Derivatives as Potent Non-Steroidal Agonists of Farnesoid X Receptor: Virtual Screening, Synthesis, and Biological Evaluation. Bioorg. Med. Chem. Lett., 2008, 18(20), 5497–5502.
106. Huang, H.; Yu, Y.; Gao, Z.; Zhang, Y.; Li, C.; Xu, X.; Jin, H.; Yan, W.; Ma, R.; Zhu, J.; Shen, X.; Jiang, H.; Chen, L.; Li, J. Discovery and Optimization of 1,3,4-Trisubstituted-Pyrazolone Derivatives as Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonists. J. Med. Chem., 2012, 55(16), 7037–7053.
107. Marinozzi, M.; Carotti, A.; Sansone, E.; Macchiarulo, A.; Rosatelli, E.; Sardella, R.; Natalini, B.; Rizzo, G.; Adorini, L.; Passeri, D.; De Franco, F.; Pruzanski, M.; Pellicciari, R. Pyrazole[3,4- e][1,4]thiazepin-7-One Derivatives as a Novel Class of Farnesoid X Receptor (FXR) Agonists. Bioorg. Med. Chem., 2012, 20(11), 3429–3445.
108. Marinozzi, M.; Carotti, A.; Sardella, R.; Buonerba, F.; Ianni, F.; Natalini, B.; Passeri, D.; Rizzo, G.; Pellicciari, R. Asymmetric Synthesis of the Four Diastereoisomers of a Novel Non-Steroidal Farnesoid X Receptor (FXR) Agonist: Role of the Chirality on the Biological Activity. Bioorg. Med. Chem., 2013, 21(13), 3780–3789.
109. Achenbach, J.; Gabler, M.; Steri, R.; Schubert-Zsilavecz, M.; Proschak, E. Identification of Novel Farnesoid X Receptor Modulators Using a Combined Ligand- and Structure-Based Virtual Screening. Medchemcomm, 2013, 4(6), 920.
110. Merk, D.; Gabler, M.; Gomez, R.C.; Flesch, D.; Hanke, T.; Kaiser, A.; Lamers, C.; Werz, O.; Schneider, G.; Schubert-Zsilavecz, M. Anthranilic Acid Derivatives as Novel Ligands for Farnesoid X Receptor (FXR). Bioorg. Med. Chem., 2014, 22(8), 2447–2460.
111. Jin, L.; Feng, X.; Rong, H.; Pan, Z.; Inaba, Y.; Qiu, L.; Zheng, W.; Lin, S.; Wang, R.; Wang, Z.; Wang, S.; Liu, H.; Li, S.; Xie, W.; Li, Y. The Antiparasitic Drug Ivermectin Is a Novel FXR Ligand That Regulates Metabolism. Nat. Commun., 2013, 4, 1937.
112. Yu, D.D.; Lin, W.; Chen, T.; Forman, B.M. Development of Time Resolved Fluorescence Resonance Energy Transfer-Based Assay for FXR Antagonist Discovery. Bioorg. Med. Chem., 2013, 21(14), 4266–4278.
113. Yu, D.D.; Lin, W.; Forman, B.M.; Chen, T. Identification of Trisubstituted-Pyrazol Carboxamide Analogs as Novel and Potent Antagonists of Farnesoid X Receptor. Bioorg. Med. Chem., 2014, 22(11), 2919–2938.
114. Xu, X.; Lu, Y.; Chen, L.; Chen, J.; Luo, X.; Shen, X. Identification of 15d-PGJ2 as an Antagonist of Farnesoid X Receptor: Molecular Modeling with Biological Evaluation. Steroids, 2013, 78(9), 813–822.
115. Liu, P.; Xu, X.; Chen, L.; Ma, L.; Shen, X.; Hu, L. Discovery and SAR Study of Hydroxyacetophenone Derivatives as Potent, Non- Steroidal Farnesoid X Receptor (FXR) Antagonists. Bioorg. Med. Chem., 2014, 22(5), 1596–1607.
116. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Medicinal Chemistry of Farnesoid X Receptor Ligands: From Agonists and Antagonists to Modulators. Future Med. Chem., 2012, 4(8), 1015–1036.
117. Howarth, D.L.; Law, S.H.W.; Law, J.M.; Mondon, J.A.; Kullman, S.W.; Hinton, D.E. Exposure to the Synthetic FXR Agonist GW4064 Causes Alterations in Gene Expression and Sublethal Hepatotoxicity in Eleutheroembryo Medaka (Oryzias Latipes). Toxicol. Appl. Pharmacol., 2010, 243(1), 111–121.
118. Chiang, P.-C.; Thompson, D.C.; Ghosh, S.; Heitmeier, M.R. A Formulation-Enabled Preclinical Efficacy Assessment of a Farnesoid X Receptor Agonist, GW4064, in Hamsters and Cynomolgus Monkeys. J. Pharm. Sci., 2011, 100(11), 4722–4733.